Literature DB >> 10707922

Outbreak of aseptic meningitis associated with mass vaccination with a urabe-containing measles-mumps-rubella vaccine: implications for immunization programs.

I Dourado1, S Cunha, M G Teixeira, C P Farrington, A Melo, R Lucena, M L Barreto.   

Abstract

A mass immunization campaign with a Urabe-containing measles-mumps-rubella vaccine was carried out in 1997 in the city of Salvador, northeastern Brazil, with a target population of children aged 1-11 years. There was an outbreak of aseptic meningitis following the mass campaign. Cases of aseptic meningitis were ascertained through data collected from the records of children admitted to the local referral hospital for infectious diseases between March and October of 1997, using previously defined eligibility criteria. Vaccination histories were obtained through home visits or telephone calls. Eighty-seven cases fulfilled the study criteria. Of those, 58 cases were diagnosed after the vaccination campaign. An elevated risk of aseptic meningitis was observed 3 weeks after Brazil's national vaccination day compared with the risk in the prevaccination period (relative risk = 14.3; 95% confidence interval: 7.9, 25.7). This result was confirmed by a case series analysis (relative risk = 30.4; 95% confidence interval: 11.5, 80.8). The estimated risk of aseptic meningitis was 1 in 14,000 doses. This study confirms a link between measles-mumps-rubella vaccination and aseptic meningitis. The authors discuss the implications of this for the organization and planning of mass immunization campaigns.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10707922     DOI: 10.1093/oxfordjournals.aje.a010239

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  19 in total

Review 1.  MMR vaccination and autism : what is the evidence for a causal association?

Authors:  Kreesten M Madsen; Mogens Vestergaard
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

2.  A global perspective on vaccine safety and public health: the Global Advisory Committee on Vaccine Safety.

Authors:  Peter I Folb; Ewa Bernatowska; Robert Chen; John Clemens; Alex N O Dodoo; Susan S Ellenberg; C Patrick Farrington; T Jacob John; Paul-Henri Lambert; Noni E Macdonald; Elizabeth Miller; David Salisbury; Heinz-J Schmitt; Claire-Anne Siegrist; Omala Wimalaratne
Journal:  Am J Public Health       Date:  2004-11       Impact factor: 9.308

3.  Close the gap for routine mumps vaccination in Japan.

Authors:  Taito Kitano
Journal:  Hum Vaccin Immunother       Date:  2020-06-12       Impact factor: 3.452

Review 4.  Vaccines for measles, mumps and rubella in children.

Authors:  Vittorio Demicheli; Alessandro Rivetti; Maria Grazia Debalini; Carlo Di Pietrantonj
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

5.  Monitoring the safety of vaccines: assessing the risks.

Authors:  Susan S Ellenberg; Miles M Braun
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 6.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2021-11-22

Review 7.  Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.

Authors:  Keri Wellington; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Knowledge synthesis of benefits and adverse effects of measles vaccination: the Lasbela balance sheet.

Authors:  Robert J Ledogar; John Fleming; Neil Andersson
Journal:  BMC Int Health Hum Rights       Date:  2009-10-14

9.  Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination.

Authors:  Silvia Perez-Vilar; Daniel Weibel; Miriam Sturkenboom; Steven Black; Christine Maure; Jose Luis Castro; Pamela Bravo-Alcántara; Caitlin N Dodd; Silvana A Romio; Maria de Ridder; Swabra Nakato; Helvert Felipe Molina-León; Varalakshmi Elango; Patrick L F Zuber
Journal:  Vaccine       Date:  2017-05-27       Impact factor: 3.641

Review 10.  Enhancing vaccine safety capacity globally: A lifecycle perspective.

Authors:  Robert T Chen; Tom T Shimabukuro; David B Martin; Patrick L F Zuber; Daniel M Weibel; Miriam Sturkenboom
Journal:  Vaccine       Date:  2015-10-01       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.